UCB posts more supportive data from Humira rival bimekizumabThere’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and Share XUCB posts more supportive data from Humira rival bimekizumabhttps://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
Humira tops list of drugs with unwarranted US price hikesAbbVie’s Humira heads a list of seven medicines that collectively contributed to a $5.1 billion increase in US Share XHumira tops list of drugs with unwarranted US price hikeshttps://pharmaphorum.com/news/humira-tops-list-of-drugs-with-unwarranted-us-price-hikes/
AbbVie prices Rinvoq close to Humira after arthritis approvalAbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price Share XAbbVie prices Rinvoq close to Humira after arthritis approvalhttps://pharmaphorum.com/news/abbvie-prices-upadacitinib-close-to-humira-after-arthritis-approval/
Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
Boehringer settles Humira lawsuit, joins biosimilar queue in USBoehringer Ingelheim was the last man standing among challengers to AbbVie’s patents on immunology blockbuster Humira but has Share XBoehringer settles Humira lawsuit, joins biosimilar queue in UShttps://pharmaphorum.com/news/boehringer-settles-humira-lawsuit-joins-biosimilar-queue-in-us/
AbbVie’s JAK inhibitor upadacitinib gets Priority ReviewAbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Share XAbbVie’s JAK inhibitor upadacitinib gets Priority Reviewhttps://pharmaphorum.com/news/abbvies-jak-inhibitor-upadacitinib-gets-priority-review/
AbbVie wobbles as biosimilars bite HumiraAbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly Share XAbbVie wobbles as biosimilars bite Humirahttps://pharmaphorum.com/news/abbvie-wobbles-as-biosimilars-bite-humira/
2018 in review: Humira biosimilars arrive in EuropeThe emergence this year of Humira biosimilars in Europe followed a period of sustained momentum around the cheaper Share X2018 in review: Humira biosimilars arrive in Europehttps://pharmaphorum.com/views-analysis-sales-marketing/2018-review-humira-biosimilars-europe/
